cisplatin,erdafitinib,cetrelimab
janssen
['bladder', 'cisplatin', 'urothelial', 'cetrelimab', 'norse']
phase 2 norse study
arlene siefker-radtke, md 55% orr, 11 months pfs and 20.8 os in cisplatin ineligible patients with erdafitonib+cetrelimab time to test fgfr alterations upon metastasis in patients with urothelial cancer #bladdercancer 
On the road! Medical Oncologist & Prof @AnkaraUni | GU cancer expert  🔬| Diversity & Equity 📢 Advocate 💫  🌍 #Oncology #GenitourinaryCancer